Trial number,Protocol code,Title of the trial,Overall trial status,Location(s) and recruitment status,Age group,Age range secondary identifier,Gender,Number of participants enrolled,Trial region,Medical conditions,Therapeutic area,Trial phase,Product,Primary endpoint,Secondary endpoints,Decision date,Start date,End date,Global end of the trial,Trial results,Sponsor/Co-Sponsors,Sponsor type,Last updated
2023-505302-42-00,UC-0107/1810,"BEPCOME-MB: Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alone in patients with BRAFV600 mutationpositive melanoma with brain metastasis","Ongoing, recruitment ended","France:Ongoing, recruitment ended","18-64 years, 65+ years",N/A,"Female, Male",150,EEA only,BRAF(V600) mutation-positive melanoma with brain metastasis (MBM),"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"KEYTRUDA 25 mg/mL concentrate for solution for infusion, Mektovi 15 mg film-coated tablets, Braftovi 50 mg hard capsules, Braftovi 75 mg hard capsules","Intracranial progression-free survival defined as the time from randomisation until IC-progressive disease (PD) as evaluated by centralised assessment using modified response evaluation criteria in solid tumours version 1.1 (RECIST v1.1), or death, whichever occurs first.","Intracranial-response rate, defined as the percentage of patients with a confirmed IC-complete response (CR) or IC-partial response (PR) as assessed by the investigator using modified RECIST v1.1., Intracranial disease control, defined as the percentage of patients with an IC-CR or IC-PR or stable intracranial disease as assessed by the investigator using modified RECIST v1.1., Extracranial response rate, defined as the percentage of patients with a confirmed EC-CR or EC-PR assessed by the investigator using RECIST v1.1., Overall response rate, defined as the percentage of patients with a confirmed CR or PR as assessed by the investigator using modified RECIST v1.1 to assess IC-response and RECIST v1.1 for EC-response., Duration of intracranial, extracranial, and overall response, defined as the time from first observation of, IC-, EC-, or overall response respectively (i.e. CR or PR), until PD according to modified RECIST v1.1 (intracranial disease) or RECIST v1.1 (extracranial disease) or death, whichever occurs first., Duration of response of treated target lesions, defined as the time from first documented response (i.e. CR or PR) as assessed by the investigator using modified RECIST v1.1, until PD of treated target lesions or death, whichever occurs first., Progression-free survival, defined as the time from randomisation until IC-PD according to modified RECIST v1.1, EC-PD according to RECIST v1.1, as assessed by the investigator, or death, whichever occurs first., Overall survival, defined as the time from randomisation until death due to any cause., Health Related Quality of Life assessed using the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires (QLQ-C30 and BN20)., Cognitive performance assessed using the Montreal Cognitive Assessment (MoCA)., Frequency and severity of adverse events assessed according to NCI-CTCAE v5.0., Other skin, laboratory, vital-sign, cardiac function, and neurological assessment data.",01/02/2024,05/09/2022,N/A,N/A,No,Unicancer,Hospital/Clinic/Other health care facility,01/02/2024
2023-508615-24-00,ECLYPse,ENCORAFENIB+CETUXIMAB BEYOND PROGRESSION IN COMBINATION WITH FOLFIRI IN PATIENTS WITH BRAF V600E MUTATED METASTATIC COLORECTAL CANCER PROGRESSING ON ENCORAFENIB + CETUXIMAB,"Ongoing, recruiting","Italy:Ongoing, recruiting","18-64 years, 65+ years",N/A,"Female, Male",25,EEA only,Patients affected by mCRC harbouring BRAF V600E,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"IRINOTECAN, FLUOROURACIL, CETUXIMAB, ENCORAFENIB, SODIUM FOLINATE","investigator-assessed 6-month progression-free survival (PFS) rate, defined as the proportion of patients alive and progression-free by the 6-month time point from start of investigational treatment. PFS is defined as the time elapsed between start of investigational treatment and the date of first event. The time-point for PFS is 6 months. Tumor assessment with CT scan of chest and abdomen will performed every 8 weeks from enrollment until evidence of disease progression or death","PFS (time elapsed from start of investigational treatment to the documentation of disease progression, according to RECIST 1.1, or death due to any cause, whichever occur first), OS (time elapsed from start of investigational treatment to the date of death due to any cause), DOR (time from response, in patients achieving CR or PR, to disease progression or death) Patients not experiencing disease progression or death will be censored at the date of the last follow-up visit., ORR (percentage of patients who achieve PR or CR as measured by RECIST 1.1 criteria), DCR (percentage of patients who achieve PR, CR or SD as measured by RECIST 1.1 criteria), Toxicity (rate of adverse events graded according to NCI-CTCAE version 4.03)",04/04/2024,03/06/2024,N/A,N/A,No,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,Hospital/Clinic/Other health care facility,04/04/2024
2024-515929-28-00,C4221008,"C4221008 - A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Non-small Cell Lung Cancer","Ongoing, recruiting","Netherlands:Ongoing, recruiting, Spain:Ongoing, recruiting, Italy:Ongoing, recruiting","18-64 years, 65+ years",N/A,"Female, Male",59,In both EEA and non-EEA,Non-small Cell Lung Cancer,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"Encorafenib, Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Braftovi 75 mg hard capsules, Braftovi 50 mg hard capsules, Braftovi 50 mg hard capsules, Mektovi 15 mg film-coated tablets","ORR defined as the proportion of patients who have achieved a confirmed best overall response (CR or PR) as determined by IRR per RECIST v1.1 in the treatment-naïve setting, ORR defined as the proportion of patients who have achieved a confirmed best overall response (CR of PR) as determined by IRR per RECIST v1.1 in the previously treated setting","Confirmed ORR by Investigator per RECIST v1.1, DOR (by IRR and by Investigator) defined as the time from the date of the first documented response (CR or PR) that is subsequently confirmed(by IRR and by Investigator, respectively) to the earliest date of disease progression, per RECIST v1.1, or death due to any cause, DCR (by IRR and by Investigator), defined as the proportion of patients who have a confirmed CR or confirmed PR, or SD per RECIST v1.1, PFS (by IRR and by Investigator), defined as the time from the date of first dose of study drug to the earliest date of disease progression, per RECIST v1.1, or death due to any cause., TTR (by IRR and Investigator), defined as the time from the date of first dose to the first documentation of objective response (CR or PR) which is subsequently confirmed (by IRR and by Investigator, respectively)",02/09/2024,02/08/2019,N/A,N/A,No,Pfizer Inc.,Pharmaceutical company,10/09/2024
2024-512038-13-00,C4221016,"C4221016 - A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma","Ongoing, recruitment ended","Italy:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Poland:Ended, Germany:Ongoing, recruitment ended, Hungary:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Finland:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Greece:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended","65+ years, 18-64 years",N/A,"Female, Male",161,In both EEA and non-EEA,Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic confirmatory  (Phase III),"KEYTRUDA 25 mg/mL concentrate for solution for infusion, Encorafenib Pacebo, ENCORAFENIB, BINIMETINIB, Binimetinib placebo","Safety Lead-In: Incidence of DLTs., Randominzed Phase 3: OR, defined as confirmed BOR of either CR or PR, as determined by BICR assessment per RECIST v1.1 from randomization to the earliest of PD, start of subsequent anticancer therapy, or death due to any cause","1. Safety Lead-In: Incidence and severity of AEs graded according to the NCI CTCAE v4.03* and changes in clinical laboratory parameters, vital signs, and cardiac assessments., 2. Safety Lead-In: OR, PFS, DC, TTR, 3. Safety Lead-In: Plasma concentration-time profiles and PK parameter estimates for encorafenib and binimetinib., 4. Randomized Phase 3: PFS, defined as the time from the date of randomization to the date of first documented disease progression, as determined by BICR assessment per RECIST v1.1, or death due to any cause, whichever occurs first.",29/05/2024,16/09/2021,N/A,N/A,No,Pfizer Inc.,Pharmaceutical company,19/08/2024
2023-509204-15-00,VHIO23001,"Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial","Ongoing, recruiting","Spain:Ongoing, recruiting","18-64 years, 65+ years","65-84 years, 85+ years","Female, Male",94,EEA only,Metastatic colorectal cancer,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"Erbitux 5 mg/mL solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules, MVASI 25 mg/mL concentrate for solution for infusion","•	Progression free survival (PFS) by local radiologist/investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 (v1.1). For the safety lead-in phase only: •	Incidence of dose-limiting toxicity (DLTs) during 1 month.","•	Incidence and severity of AEs graded according to the NCI CTCAE v5.0 and changes in clinical laboratory parameters, vital signs and ECGs during the treatment until 30+/-2 days after EOT. •	Incidence of dose delays, dose modifications and discontinuations due to AEs., •	Overall Response Rate (ORR) per RECIST v1.1, defined as the number of patients achieving an overall best response of complete response (CR) or partial response (PR) divided by the total number of patients.  •	Time to response, defined as the time from first dose to first radiographic evidence of response.  •	Duration of Response (DOR), defined as the time from first radiographic evidence of response to the earliest documented disease progression or death due to underlying disease., •	Overall Survival (OS), defined as the time from first dose to death due to any cause., •	Change in PRO as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Patients (QLQ-C30) and Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C).",08/02/2024,17/05/2024,N/A,N/A,No,Vall D Hebron Institute Of Oncology,Laboratory/Research/Testing facility,08/02/2024
2023-509408-13-00,C4221026,C4221026: ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES,"Ongoing, recruiting","Portugal:Ongoing, recruiting, Czechia:Ongoing, recruiting, Hungary:Ongoing, recruiting, France:Ongoing, recruiting, Netherlands:Ongoing, recruiting, Germany:Ongoing, recruiting, Italy:Ongoing, recruiting, Spain:Ongoing, recruiting","18-64 years, 65+ years",85+ years,"Female, Male",36,In both EEA and non-EEA,Solid tumors,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic use (Phase IV),"Mektovi 15 mg film-coated tablets, Braftovi 75 mg hard capsules, Ribociclib, Erbitux 5 mg/mL solution for infusion, Zelboraf 240 mg film-coated tablets, Encorafenib, Ribociclib, Mektovi 15 mg film-coated tablets, Braftovi 50 mg hard capsules, Braftovi 75 mg hard capsules, Ribociclib, Braftovi 50 mg hard capsules","AEs leading to permanent discontinuation of study interventiona, All SAEs",N/A,27/08/2024,20/09/2022,N/A,N/A,No,Pfizer Inc.,Pharmaceutical company,26/09/2024
2024-514107-34-00,FFCD 2006 NEORAF,"FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING IN PATIENTS WITH BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER","Authorised, recruitment pending","France:Authorised, recruitment pending","65+ years, 18-64 years",N/A,"Female, Male",30,EEA only,BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER,"[""Diseases [C] - Neoplasms [C04]"",""Diseases [C] - Digestive System Diseases [C06]""]",Therapeutic exploratory (Phase II),"Erbitux 5 mg/mL solution for infusion, Braftovi 75 mg hard capsules","The primary endpoint of the study is the tumour regression rate (TRG0 to TRG2) assessed with Ryan’s modified score from the AJCC 2010 (ref: Edge SB, et al. 3rd AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010.) in the level of the primary tumour, after surgery and centralised review.","Overall safety of treatment, Overall survival, Progression-free survival, The response rate in CT-scan according to RECIST 1.1 criteria, Post-operative morbidity and mortality, Quality of life (EQ5D)",18/07/2024,N/A,N/A,N/A,No,Fondation Franc.Cancerologie Digestive,Hospital/Clinic/Other health care facility,18/07/2024
2022-502267-37-00,Z0011001 (ZN-c3-016),"Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER","Ongoing, recruiting","Poland:Ongoing, recruiting, Spain:Ongoing, recruiting, Germany:Ongoing, recruiting, Hungary:Ongoing, recruiting, Italy:Ongoing, recruiting",18-64 years,N/A,"Female, Male",50,In both EEA and non-EEA,metastatic colorectal cancer,"[""Diseases [C] - Neoplasms [C04]""]",Phase I and Phase II (Integrated)- Other,"CETUXIMAB, ENCORAFENIB","Dose escalation: Incidence of DLTs (dose-limiting toxicities)., Expansion cohort: ORR by Investigator, defined as the proportion of participants who have achieved a confirmed BOR of CR or PR per RECIST version 1.1.","Escalation: Incidence and severity of AEs graded according to the NCI CTCAE v5.0 and changes in clinical laboratory parameters, vital signs and ECGs. Incidence of dose interruptions, dose modifications and discontinuations due to AEs., Escalation: ORR, DOR, PFS, DCR and TTR by Investigator., Escalation: Plasma PK parameters of ZN-c3 (and its potential metabolites as applicable), including but not limited to Cmax, Tmax, and AUC., Escalation: Plasma PK parameters of encorafenib including but not limited to Cmax, Tmax, and AUC., Expansion: DOR, PFS, DCR and TTR by Investigator., Expansion: Incidence and severity of AEs graded according to the NCI CTCAE v5.0 and changes in clinical laboratory parameters, vital signs and ECGs. Incidence of dosing interruptions, dose modifications and discontinuations associated with AEs., Expansion: Plasma PK parameters of ZN-c3 (and its potential metabolites as applicable), including but not limited to Cmax, Tmax, and AUC., Expansion: Plasma PK parameters of encorafenib including but not limited to Cmax, Tmax, and AUC., Expansion: Plasma PK parameters of ZN-c3 including but not limited to Cmax and AUC., Expansion: BRAF V600E mutational status.",16/06/2023,17/07/2023,N/A,N/A,No,K-Group Beta Inc.,Pharmaceutical company,13/05/2024
2022-502413-29-00,TTD-21-02,Multicenter Phase 2 study to evaluate the efficacy and safety of Cetuximab in combination with Encorafenib plus Binimetinib as induction treatment in BRAF V600E mutated MSS initially resectable or potentially resectable advanced colorectal cancer.,"Ongoing, recruiting","Spain:Ongoing, recruiting","65+ years, 18-64 years",N/A,"Female, Male",70,EEA only,BRAF V600E mutated and microsatellite stable (MSS) advanced colorectal cancer (aCRC) initially resectable or potentially resectable,"[""Diseases [C] - Digestive System Diseases [C06]"",""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets, Erbitux 5 mg/mL solution for infusion","Radical treatment rate, defined as the number of patients radically treated for their primary tumor and/or distant metastases by surgery and/or by any other radical therapeutic procedure with curative intent (i.e. radiofrequency, cryotherapy, laserhyperthermia, stereotactic body radiotherapy or chemoembolization)., In case of patients undergoing surgery, the proportion of patients achieving R0 (microscopically margin-negative resection) or R1 (microscopic residual margin affected) will be assessed. For the rest of procedures, the achievement of complete tumor removal/destruction will be considered., The eligibility of each individual patient for radical treatment will be evaluated at 12 or 24 weeks after the first dose of study treatment by the MTB. If a patient is eligible, radical treatment will be performed al least 2 weeks after the end of EBC treatment and at the lasest, 10 weeks after the lastest CT evaluation.","Overall response rate (ORR), defined as the number of patients achieving complete response (CR) or partial response (PR) as best response according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, divided by the total number of patients., Tumor regression grade (TRG), after any surgical treatment of the primary tumor and/or distant metastases defined as five histological categories as follows: TRG1, no residual tumor; TRG2, microscopic residual tumor; TRG3, moderate response; TRG4, minor response; and TRG5, no response., Progression-free-survival (PFS), defined as the time in months from first dose of study treatment to disease progression or death (due to any cause). Patients lost to follow-up progression free and alive at the end of the study, will be censored, in K-M analysis, at the date last known to be alive and progression free., Overall survival (OS), defined as the time in months from first dose of study treatment to death due to any cause. Patients lost to follow-up or alive at the end of the study, will be censured, in K-M analysis, at the date known to be alive., Disease free survival (DFS), defined as the time in months from first dose of study treatment to cancer recurrence, second cancer, or death from any cause in resected patients. Patients lost to follow-up or disease free and alive at the end of the study, will be censores, in K-M analysis, at the date last known to be alive and disease free., Complications related to surgery and/or any other therapeutic procedure for radical treatment ocurring within 60 days after surgery (i.e. perioperative mortality, transfusions, hemorrhage, infections, wound healing, general or local complications). Incidence and severity of adverse events (AEs) graded according to the NCI CTCAE v4.03 and changes in clinical laboratory parameters and vital signs.",30/10/2023,22/01/2024,N/A,N/A,No,Asociacion Grupo Tratamiento De Tumores Digestivos,Patient organisation/association,30/10/2023
2024-512119-34-00,C4221022,"C4221022 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI-H/DMMR METASTATIC COLORECTAL CANCER","Ongoing, recruiting","Czechia:Ongoing, recruiting, Germany:Ongoing, recruiting, France:Ongoing, recruiting, Denmark:Ongoing, recruiting, Sweden:Authorised, recruiting, Poland:Ongoing, recruiting, Belgium:Ongoing, recruiting, Norway:Ongoing, recruiting, Netherlands:Ongoing, recruiting, Spain:Ongoing, recruiting, Slovakia:Ongoing, recruiting, Italy:Ongoing, recruiting","18-64 years, 0-17 years, 65+ years",12-17 years,"Female, Male",75,In both EEA and non-EEA,MSI-H/dMMR metastatic colorectal cancer,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB","PFS per investigator, defined as the time from randomization until PD based on investigator assessment per RECIST v1.1 or death due to any cause, whichever occurs first","Incidence and severity of AEs graded according to the NCI CTCAE v4.03 and changes in clinical laboratory test parameters, vital signs and ECGs, - Incidence of dosing interruptions, dose modifications and permanent discontinuations associated with AEs, - OS, defined as the time from the date of randomization to the date of death due to any cause, - Objective response, defined as confirmed CR or confirmed PR based on investigator assessment per RECIST v1.1, from the date of randomization until the date of the first documentation of PD, death or start of new anticancer therapy, - DOR, defined as the time from the first response, until PD based on investigator assessment per RECIST v1.1 or death due to any cause, whichever occurs first, BRAF and MSI-status as determined by retrospective central testing of baseline tumor tissue;, EORTC QLQ-C30: change from baseline in the global health status/QoL, functional and symptom scales, and single items, - EQ-5D-5L: change from baseline in the index score and VAS, - PGIS score: change from baseline in the score, - PGIC score",18/07/2024,20/06/2022,N/A,N/A,No,Pfizer Inc.,Pharmaceutical company,08/08/2024
2023-505376-30-00,EORTC 1612-MG,EORTC 1612-MG: Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) vs immediate combination of immunotherapy in patients with unresectable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN),"Ongoing, recruitment ended","Netherlands:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, France:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended","18-64 years, 65+ years",N/A,"Female, Male",264,In both EEA and non-EEA,BRAF V600 mutation–positive unresectable or metastatic melanoma,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, Braftovi 75 mg hard capsules, YERVOY 5 mg/ml concentrate for solution for infusion, Mektovi 15 mg film-coated tablets","Progression-free survival (PFS): defined as the time from the date of randomization until the first date of progression, or until date of death (whatever the cause), whichever occurs first. For patients who remain alive and whose disease has not progressed, PFS will be censored on the date of last visit/contact when a disease assessment was performed. PFS will be based on the disease assessment or date of death provided by the local investigator","Overall survival (OS): defined as the time from the date of randomization to the date of death, whatever the cause. The follow-up of patients still alive will be censored at the moment of last visit/contact, CR rate, time to CR and duration of CR, Best overall objective response (CR+PR) rate (ORR), time to best objective reponse (OR) and duration of OR",25/06/2024,30/10/2018,N/A,N/A,No,European Organisation For Research And Treatment Of Cancer,Patient organisation/association,09/09/2024
2023-509405-77-00,C4221015,"C4221015 - AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY
VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E MUTANT COLORECTAL CANCER","Ongoing, recruitment ended","Germany:Ongoing, recruitment ended, Finland:Ongoing, recruitment ended, Spain:Ongoing, recruitment ended, Belgium:Ongoing, recruitment ended, Norway:Ongoing, recruitment ended, Czechia:Ongoing, recruitment ended, Denmark:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Sweden:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended, Bulgaria:Ongoing, recruitment ended, Netherlands:Ongoing, recruitment ended","18-64 years, 65+ years, 0-17 years",N/A,"Female, Male",300,In both EEA and non-EEA,Colorectal cancer (BRAF V600E-mutant mCRC),"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic confirmatory  (Phase III),"Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, Capecitabine, Calcium Folinate 10 mg/ml Injection, CAPECITABINE, ENCORAFENIB, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, OXALIPLATIN, Bevacizumab, FLUOROURACIL, Cetuximab, CALCIUM FOLINATE, CAPECITABINE, Oxaliplatin 5mg/ml concentrate for Solution for Infusion, IRINOTECAN, Fluorouracil 50 mg/ml Solution for Injection or Infusion, CETUXIMAB, CAMPTO 20 mg/mL concentrate for solution for infusion, BEVACIZUMAB","Safety Lead-In: Incidence of dose-limiting toxicities (DLTs), Phase 3: • PFS by blinded independent central review (BICR), defined as the time from the date of randomization to the earliest documented disease progression per RECIST v1.1, or death due to any cause • ORR by BICR, Cohort 3: • ORR by BICR","Safety Lead-In: Incidence and severity of adverse events (AEs) graded according to the National Cancer Institute (NCI ) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 and changes in clinical laboratory parameters, vital signs and electrocardiograms (ECGs), Safety Lead-In: Incidence of dose interruptions, dose modifications and discontinuations due to AEs, Safety Lead-In: ORR by Investigator, defined as the proportion of participants who have achieved a confirmed best overall response (BOR) (complete response [CR] or partial response [PR]) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Safety Lead-In: Duration of response (DOR) by Investigator, defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented disease progression per RECIST v1.1, or death due to any cause, Safety Lead-In: Progression-free survival (PFS) by Investigator, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause, Safety Lead-In: Time to response (TTR) by Investigator, defined as the time from first dose to first radiographic evidence of response (CR or PR) per RECIST v1.1, Safety Lead-In: Overall survival (OS) defined as the time from the first dose to death due to any cause, Safety Lead-In: PK parameters of encorafenib, irinotecan, oxaliplatin and relevant metabolites, Safety Lead-In: Changes in exposures of irinotecan and its metabolite (SN-38) on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 1 (EC + FOLFIRI), Safety Lead-In: Changes in exposures of oxaliplatin on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 2 (EC + mFOLFOX6), Phase 3: - OS, defined as the time from the date of randomization to death due to any cause, Phase 3: - ORR by Investigator, Phase 3: - ORR by BICR (Arm A vs Control Arm, Arm A vs Arm B), Phase 3: - DOR by BICR and by Investigator, Phase 3: - PFS by BICR (Arm A vs Control Arm, Arm A vs Arm B), Phase 3: - OS (Arm A vs Control Arm, Arm A vs Arm B), Phase 3: - PFS by Investigator  -	TTR (by BICR and by Investigator), defined as the time from the date of randomization to first radiographic evidence of response (CR or PR) per RECIST v1.1, Phase 3: -PFS2, defined as the time from the date of randomization to the date of discontinuation of next-line treatment after first objective PD by investigator assessment, the second objective disease progression, or death from any cause, whichever occurs first, Phase 3:- Incidence and severity of AEs graded according to the NCI CTCAE v4.03 and changes in clinical laboratory parameters, vital signs, and ECGs, Phase 3: - PRO scores as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients – 30 Item Core Questionnaire (EORTC QLQ-C30), EuroQol-5D-5L (EQ-5D-5L), and anchoring instruments Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC)., Phase 3:- Trough plasma concentrations of encorafenib and the metabolite LHY746 in Arm A and Arm B, Phase 3: - PK parameters of encorafenib and its metabolite LHY746, Phase 3:- Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue, Phase 3: - ctDNA levels and BRAF V600 variant allele fraction (VAF) from ctDNA analysis of plasma samples collected at baseline and on treatment, Cohort 3: -PFS by BICR, defined as the time from the date of randomization to the earliest documented disease progression per RECIST v1.1, or death due to any cause, Cohort 3:  -ORR by Investigator, Cohort 3: -DOR by BICR and by Investigator, defined as the time from the date of first radiographic evidence of response (CR or PR) to the earliest documented disease progression per RECIST v1.1, or death due to any cause, Cohort 3:- PFS by Investigator, defined as the time from the date of randomization to the earliest documented disease progression per RECIST v1.1, or death due to any cause, Cohort 3:--OS, defined as the time from the date of randomization to death due to any cause, Cohort 3:- TTR (by BICR and by Investigator), defined as the time from the date of randomization to first radiographic evidence of response (CR or PR) per RECIST v1.1, Cohort 3:- Incidence and severity of AEs graded according to the NCI CTCAE v4.03 and changes in clinical laboratory parameters, vital signs, and ECGs, Cohort 3:- PRO scores as measured by the EORTC QLQ-C30, EQ-5D-5L, and anchoring instruments PGIS and PGIC, Cohort 3:Trough plasma concentrations of encorafenib and the metabolite LHY746 in Cohort 3 Arm D, Cohort 3:- Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue, Cohort 3:- ctDNA levels and BRAF V600 VAF from ctDNA analysis of plasma samples collected at baseline and on treatment",10/04/2024,16/02/2021,N/A,N/A,No,Pfizer Inc.,Pharmaceutical company,25/09/2024
2023-509471-17-00,C4221023,"C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY","Ongoing, recruitment ended","Spain:Ongoing, recruitment ended, Germany:Ongoing, recruitment ended, Slovakia:Ongoing, recruitment ended, Italy:Ongoing, recruitment ended, Poland:Ongoing, recruitment ended","65+ years, 18-64 years",N/A,"Female, Male",119,In both EEA and non-EEA,Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanoma,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"IPILIMUMAB, NIVOLUMAB, IPILIMUMAB, PEMBROLIZUMAB, BINIMETINIB, ENCORAFENIB","ORR, defined as the proportion of participants with a confirmed best overall response of either CR or PR, as determined by investigator assessment per RECIST v1.1 from randomization to the earliest of PD, start of subsequent anticancer therapy, or death due to any cause.","PFS, defined as the interval of time between the date of randomization to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause, whichever occurs first., OS, defined as the time from date of randomization to the date of death due to any cause or the last known alive date., DOR, defined as the time from the date of the first documented response (CR or PR) to the earliest date of disease progression, as determined by investigator assessment per RECIST v1.1, or death due to any cause., DCR, defined as the proportion of participants with a confirmed best overall response of CR, PR or SD, as determined by investigator assessment per RECIST v1.1., TTR, defined as the time from the date of randomization to the date of first documented response (CR or PR), as determined by investigator assessment per RECIST v1.1., PFS2, defined as the time from the date of randomization to the date of discontinuation of next-line treatment after first objective disease progression by investigator assessment per RECIST v1.1, second objective disease progression after initiation of next-line treatment, as determined by investigator assessment, or death due to any cause, whichever occurs first., Incidence and severity of AEs, and changes in clinical laboratory parameters, vital signs, and cardiac assessments., EORTC QLQ-C30: change from baseline in the global health status/QoL score and all other subscales scores., EQ-5D-5L: change from baseline in the index score and VAS., BRAF V600E/K VAF and/or overall mean VAF from ctDNA analysis of plasma samples collected at baseline and on treatment.",07/06/2024,24/05/2023,N/A,N/A,No,Pfizer Inc.,Pharmaceutical company,18/07/2024
2023-509088-26-00,N/A,Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAF V600E mutated mCRC. BRICKET study,"Ongoing, recruiting","Italy:Ongoing, recruiting","18-64 years, 65+ years",N/A,"Female, Male",16,EEA only,Metastatic colorectal cancer,"[""Diseases [C] - Digestive System Diseases [C06]"",""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"Erbitux 5 mg/mL solution for infusion, Braftovi 75 mg hard capsules","Objective Response Rate (ORR) defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria. The determination of clinical response will be based on investigator-reported measurements. Responses will be evaluated with a chest and abdominal computed tomography (CT) scan every 8 weeks.","Progression Free Survival (PFS) is defined as the time interval computed from the date of study enrollment to the date of objective progression according to the RECIST criteria (version 1.1) or death, whatever comes first., Overall survival (OS) is defined as the time from the date of study enrollment to the date of death due to any cause. For patients still alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive., Overall Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled subjects, experiencing any adverse event, according to National Cancer Institute Common Toxicity Criteria (version 5.0), G3/4 Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled subjects, experiencing a specific adverse event of grade 3/4, according to National Cancer Institute Common Toxicity Criteria (version 5.0), Early Objective Response Rate (EORR) is defined as the percentage of patients, relative to the total of the enrolled subjects, achieving a ≥20% decrease in the sum of diameters of RECIST target lesions at week 8 compared to baseline, Depth of Response (DpR) is defined as the relative change in the sum of longest diameters of RECIST target lesions at the nadir, in the absence of new lesions or progression of non-target lesions, when compared with baseline, Clinical outcomes of the screening failure population include collection of therapeutic choices after ctDNA screening; ORRfailure; PFSfailure of the first line after ctDNA screening; OSfailure. For patients still alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive., Quality of Life (QoL) is assessed using the EORTC QLQ-C30 and the EORTC QLQ-CR29 questionnaires, will be evaluated from patients who have completed at least one questionnaire item at baseline and during the study period through descriptive summary statistics., Time To Deterioration in Quality of Life (TTD) is defined as the time from baseline to the first onset of a 10-point or greater decrease from study enrollment for functional scales or a 10- point or greater increase for symptom scales or death.",21/06/2024,22/07/2024,N/A,N/A,No,Gruppo Oncologico Del Nord Ovest,Patient organisation/association,21/06/2024
2024-514087-11-02,N/A,A phase-2 clinical trial of regorafenib in patients with pretreated advanced melanoma,"Authorised, recruitment pending","Belgium:Authorised, recruitment pending","65+ years, 18-64 years",N/A,"Female, Male",36,EEA only,Melanoma,"[""Diseases [C] - Skin and Connective Tissue Diseases [C17]""]",Therapeutic exploratory (Phase II),Stivarga 40 mg film-coated tablets,"Objective response rate (ORR; defined as  the percentage of subjects with a confirmed  complete response [CR] or partial response  [PR] at any time per Response Evaluation  Criteria in Solid Tumors [RECIST], version  1.1, [4])","Disease control rate (DCR; defined as the  percentage of subjects with a confirmed  stable disease (SD), partial response (PR)  or complete response (CR) at any time per  Response Evaluation Criteria in Solid  Tumors (RECIST), version 1.1. [4]), Objective response rate (ORR; defined as  the percentage of subjects with a confirmed  complete response [CR] or partial response  [PR] at any time per Response Evaluation  Criteria in Solid Tumors [RECIST], version  1.1, [4] and RANO-BM criteria [5])  determined separately for extra- and intracranial metastases, respectively., Progression-free survival (PFS; defined as  the time from the date of the first dose of  regorafenib until the earliest date of  documented disease progression [per  RECIST v1.1] or death due to any cause)  and overall survival (OS; defined as the  time from the date of the first dose of  regorafenib until the date of death due to  any cause)., Safety as assessed by anamnesis, clinical  examination, analysis of blood and urine,  electrocardiograms, cardiac  echocardiography, and any additional  medical examination that is indicated. AE  will be graded by the Common Terminology  Criteria of Adverse events (CTCAE), version  5.0 (National Institutes of Health, National  Cancer Institute)., Duration of response (DOR; defined as the  time from the date of first documented  response (SD, PR or CR) until the earliest  date of documented disease progression.,  The generic health status of the  patients will be assessed by means of  the EuroQOL-5D-3L (EQ-5D-3L).  Health-related quality of life (HRQoL)  will be assessed with the European  Organization for Research and  Treatment of Cancer quality of life  questionnaire-C30 (EORTC-QLQ-C30).  Melanoma specific health-related  quality of life will be evaluated with the  Functional Assessment of Cancer  Therapy-Melanoma questionnaire  (FACT-M)",20/09/2024,N/A,N/A,N/A,No,UZ Brussel,Hospital/Clinic/Other health care facility,20/09/2024
2023-508090-87-00,N/A,A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants with Selected Advanced PIWIL1-Positive Cancers,"Authorised, recruiting","Italy:Authorised, recruitment pending, Germany:Authorised, recruitment pending, Netherlands:Authorised, recruitment pending, France:Authorised, recruitment pending, Belgium:Ongoing, recruiting, Spain:Authorised, recruitment pending","18-64 years, 65+ years","65-84 years, 85+ years","Female, Male",35,In both EEA and non-EEA,Advanced cancers that are PIWIL1-positive,"[""Diseases [C] - Neoplasms [C04]""]",Phase I and Phase II (Integrated)- First administration to humans,"CALCIUM FOLINATE, CALCIUM FOLINATE, FLUOROURACIL, CAPECITABINE, BEVACIZUMAB, CAPECITABINE, CETUXIMAB, ENCORAFENIB, IMC-R117C","Dose escalation: •	Incidence of DLTs •	Incidence and severity of AEs and SAEs,  •	Changes in QTcF, vital signs, and safety diagnostic parameters •	Incidence of dose interruptions, reductions, and discontinuations, Expansion:  •	BOR by RECIST v1.1 per investigator, Regimen optimization: •	Compare safety of the 2 selected monotherapy or combination regimens based on incidence of DLTs, incidence and severity of AEs and SAEs, dose interruptions, reductions, and discontinuations, Regimen optimization: •	Compare the efficacy of the 2 selected monotherapy or combination regimens based on BOR, PFS, and DCR-8 months, changes in tumor growth kinetics, changes in levels of tumor markers and ctDNA over time compared to baseline, Phase 2: PFS per BICR","Dose escalation: •	BOR, DOR and PFS per investigator •	Overall survival Expansion:  •	DOR and PFS per investigator •	Overall survival •	Incidence and severity of AEs and SAEs •	Change in QTcF, vital signs, and safety diagnostic parameters •	Incidence of dose interruptions, reductions, and discontinuations, Phase 2:  •	Overall survival •	ORR per BICR •	Incidence and severity of AEs and SAEs •	Change in QTcF, vital signs, and safety diagnostic parameters •	Incidence of dose interruptions, reductions, and discontinuations, All study parts (excluding Phase 2 standard of care arm):  •	IMC-R117C PK parameters (e.g, AUC, Cmax, Tmax,  t1/2) after single and multiple doses •	Incidence of anti-IMC-R117C antibody formation •	Tumor expression and localization of PIWIL1",23/04/2024,09/10/2024,N/A,N/A,No,Immunocore Limited,Pharmaceutical company,30/09/2024
2024-516585-11-00,N/A,Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial,"Ongoing, recruiting","Denmark:Ongoing, recruiting","65+ years, 18-64 years",N/A,"Female, Male",50,EEA only,Advanced melanoma,"[""Diseases [C] - Neoplasms [C04]""]",Therapeutic exploratory (Phase II),"DABRAFENIB, ENCORAFENIB, BINIMETINIB, TRAMETINIB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.","6 months progression-free survival rate, 6 months overall survival rate","Overall progression-free survival, Overall survival, Overall response rate according to modified RECIST 1.1, Extracranial response rate in extracranial lesions according to modified RECIST 1.1, Intracranial response rate in intracranial lesions according to modified RECIST 1.1, Intracranial clinical benefit rate (CR+PR+SD) – proportion of patients with an overall complete, partial response or stable disease ≥ 6 months according to modified RECIST 1.1, Blood and tissue biomarkers of response and progression",26/08/2024,12/06/2018,N/A,N/A,No,Region Hovedstaden,Hospital/Clinic/Other health care facility,26/08/2024